Dimitrios Kontothanassis: The Role of Thermal Ablation in GSV Reflux Treatment – LIVE 2026
Dimitrios Kontothanassis, Director of the Italian Phlebology Institute, shared a post on LinkedIn:
“It was a true honor to participate in LIVE 2026 (Leading Innovation Vascular Education) in Thessaloniki, Greece, and to present on the leading role of thermal ablative therapies in the treatment of great saphenous vein reflux.
Although endovenous thermal ablation remains a cornerstone in the treatment of varicose vein disease, it is increasingly important to clearly define the role of each thermal and tumescent technology — including Laser and Radiofrequency — as well as emerging thermal and non-tumescent modalities such as HIFU.
It was a pleasure to engage in such a stimulating debate and exchange ideas with internationally renowned colleagues on the priorities and evolving strategies in venous disease management.
Chronic venous disease remains, for many patients, a long-term condition that cannot yet be definitively cured, making continuous innovation and scientific collaboration essential.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’